Galecto Biotech's CMO discusses the company's recent EUR 79m Series C financing

Richard Marshall, chief medical officer at Galecto Biotech, talks to Scrip mananging editor Jo Shorthouse about how a recent financing will allow the galectin modulator company to quickly push forward its product for idiopathic pulmonary fibrosis. He also discusses the company's work in the oral and ocular therapeutic areas.